High Lipoprotein(a) Levels and Small Apolipoprotein(a) Size Prospectively Predict Cardiovascular Events in Dialysis Patients
Open Access
- 1 June 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (6) , 1794-1802
- https://doi.org/10.1681/asn.2004110922
Abstract
Lipoprotein(a) [Lp(a)] levels are increased in dialysis patients, suggesting that they may play a role in the elevated atherosclerotic cardiovascular disease (ASCVD) risk in this population. Few prospective studies of Lp(a) level, apolipoprotein(a) [apo(a)] size, and ASCVD have been performed in the dialysis population. An inception cohort of 833 incident dialysis patients were followed prospectively. Baseline Lp(a) was measured by apo(a) size-independent ELISA and apo(a) size by Western blot after SDS–agarose gel electrophoresis. A combined prospective nonfatal and fatal ASCVD end point included myocardial infarction, coronary revascularization, cerebrovascular accident, carotid endarterectomy, peripheral revascularization, gangrene, or limb amputation. Survival analyses were performed with adjustment for baseline demographics, comorbid conditions, ASCVD risk factors, albumin, lipids, and C-reactive protein. Median follow-up was 27.4 mo, with 297 ASCVD events, 130 non-ASCVD deaths, and seven losses to follow-up over 1649 person-years. In multivariate Cox regression models, both high Lp(a) concentration (≥53 nmol/L) and low molecular weight (LMW) apo(a) isoforms (≤22 Kringle-IV repeats) predicted ASCVD events (relative hazard [RH] = 1.38, P = 0.02; RH = 1.58, P < 0.0005, respectively). In models that included both Lp(a) concentration and apo(a) size, only apo(a) size remained associated with ASCVD. Among those with both LMW apo(a) and Lp(a) level >123 nmol/L, the relative hazard (RH) of ASCVD was 1.73 (P < 0.0005), compared with high molecular weight apo(a) and Lp(a) level <123 nmol/L. No interactions by age, race, gender, diabetes, or ASCVD were present. Both LMW apo(a) size and high Lp(a) level predict ASCVD risk in dialysis patients, but the association of ASCVD with LMW isoforms is stronger than the association with high Lp(a) concentration.Keywords
This publication has 23 references indexed in Scilit:
- Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future DirectionsClinical Chemistry, 2003
- Role of Lipoprotein(a) and Apolipoprotein(a) Phenotype in AtherogenesisCirculation, 1999
- Lipoprotein(a) Concentration and Apolipoprotein(a) SizeCirculation, 1999
- Apolipoprotein(a) isoforms and coronary heart disease in men: A nested case-control studyAtherosclerosis, 1997
- Lipoprotein(a): structural implications for pathophysiologyInternational Journal of Clinical and Laboratory Research, 1997
- A Prospective Case-Control Study of Lipoprotein(a) Levels and Apo(a) Size and Risk of Coronary Heart Disease in Stanford Five-City Project ParticipantsArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Lipoprotein(a) in renal diseaseAmerican Journal of Kidney Diseases, 1996
- Identification of 34 Apolipoprotein(a) Isoforms: Differential Expression of Apolipoprotein(a) Alleles between American Blacks and WhitesBiochemical and Biophysical Research Communications, 1993
- Apo(a) isoforms predict risk for coronary heart disease. A study in six populations.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Lipoprotein a inhibits streptokinase-mediated activation of human plasminogenBiochemistry, 1989